CY1113191T1 - Συνθεση συμπιεσμενων δισκιων εφαβιρενζης - Google Patents

Συνθεση συμπιεσμενων δισκιων εφαβιρενζης

Info

Publication number
CY1113191T1
CY1113191T1 CY20121100778T CY121100778T CY1113191T1 CY 1113191 T1 CY1113191 T1 CY 1113191T1 CY 20121100778 T CY20121100778 T CY 20121100778T CY 121100778 T CY121100778 T CY 121100778T CY 1113191 T1 CY1113191 T1 CY 1113191T1
Authority
CY
Cyprus
Prior art keywords
compacted
discs
effective
composition
efavirenz
Prior art date
Application number
CY20121100778T
Other languages
English (en)
Inventor
Udit Batra
Raymond J Higgins
Karen C Thompson
Ashok V Katdare
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815800.9A external-priority patent/GB9815800D0/en
Priority claimed from EP03076054A external-priority patent/EP1332757B1/en
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1113191T1 publication Critical patent/CY1113191T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

Η εφεύρεση αφορά μια σύνθεση συμπιεσμένου δισκίου εφαβιρένζης, το οποίο φορτίζεται με 50% κατά βάρος δραστική ουσία. Η εφαβιρένζη είναι ένας μη νουκλεοσιδικός αναστολέας της αντίστροφης τρανσκριπτάσης, ο οποίος μελετάται κλινικά για χρήση εις τη θεραπευτική αγωγή μολύνσεων ΗIV και ΑΙDS.
CY20121100778T 1998-05-27 2012-08-29 Συνθεση συμπιεσμενων δισκιων εφαβιρενζης CY1113191T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8692198P 1998-05-27 1998-05-27
GBGB9815800.9A GB9815800D0 (en) 1998-07-21 1998-07-21 Compressed tablet formulation
EP03076054A EP1332757B1 (en) 1998-05-27 1999-05-24 Efavirenz compressed tablet formulation

Publications (1)

Publication Number Publication Date
CY1113191T1 true CY1113191T1 (el) 2016-04-13

Family

ID=26314071

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100778T CY1113191T1 (el) 1998-05-27 2012-08-29 Συνθεση συμπιεσμενων δισκιων εφαβιρενζης

Country Status (14)

Country Link
EP (1) EP1083901B1 (el)
JP (1) JP4000354B2 (el)
AT (1) ATE237332T1 (el)
AU (1) AU761182B2 (el)
CA (1) CA2332876C (el)
CO (1) CO5070643A1 (el)
CY (1) CY1113191T1 (el)
DE (1) DE69906963D1 (el)
DK (1) DK1332757T3 (el)
ES (1) ES2388849T3 (el)
PE (1) PE20000559A1 (el)
PT (1) PT1332757E (el)
SI (1) SI1332757T1 (el)
WO (1) WO1999061026A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
EP3025718A1 (en) 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7198653B2 (en) * 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
JP2005089396A (ja) * 2003-09-19 2005-04-07 Pola Chem Ind Inc イソフラボン含有経口投与組成物
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
JP2010536798A (ja) * 2007-08-17 2010-12-02 テバ ファーマシューティカル インダストリーズ リミティド 難溶性薬物の生体利用率を制御するための方法及び組成物
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CA2796494A1 (en) 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical composition
US20120115799A1 (en) * 2010-05-11 2012-05-10 Wenhua Wang Pharmaceutical formulations
EP2441759A1 (en) 2010-10-14 2012-04-18 Lonza Ltd. Process for the synthesis of cyclic carbamates
EP2447255A1 (en) 2010-10-14 2012-05-02 Lonza Ltd. Process for the synthesis of cyclic carbamates
RU2661402C2 (ru) * 2011-10-17 2018-07-16 Лексикон Фармасьютикалз, Инк. Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции
CN113499441A (zh) * 2021-08-05 2021-10-15 上海合全医药有限公司 一种药用糖包衣液及其制备方法
CN113999543B (zh) * 2021-10-29 2022-11-04 广西华纳新材料股份有限公司 一种钙-硅核壳结构纳米碳酸钙的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
AR012702A1 (es) * 1997-05-17 2000-11-08 Glaxo Group Ltd Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente

Also Published As

Publication number Publication date
ATE237332T1 (de) 2003-05-15
SI1332757T1 (sl) 2012-10-30
CO5070643A1 (es) 2001-08-28
JP4000354B2 (ja) 2007-10-31
DE69906963D1 (de) 2003-05-22
CA2332876C (en) 2008-07-08
WO1999061026A1 (en) 1999-12-02
JP2002516281A (ja) 2002-06-04
PE20000559A1 (es) 2000-07-05
CA2332876A1 (en) 1999-12-02
PT1332757E (pt) 2012-09-03
ES2388849T3 (es) 2012-10-19
DK1332757T3 (da) 2012-09-24
AU4201099A (en) 1999-12-13
EP1083901A1 (en) 2001-03-21
EP1083901B1 (en) 2003-04-16
AU761182B2 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
CY1113191T1 (el) Συνθεση συμπιεσμενων δισκιων εφαβιρενζης
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP1268412B8 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
BR0107869A (pt) Composições farmacêuticas eletrogiradas
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
BG106030A (en) Pharmaceutical composition
ID27504A (id) Formulasi oral baru
HUP0003784A2 (hu) Fájdalmas menstruáció és koraszülés kezelésére alkalmas gyógyászati készítmény
BRPI0308663B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
IS2789B (is) Lyfjablöndur sem innihalda mónóamínoxídasa B hemla
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
ATE219061T1 (de) Huperzin a analoge verbindungen
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
HUP0400553A2 (hu) Gyógyászati készítmények
HUP0004544A2 (hu) Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására
DK1069902T3 (da) Anvendelse af phospholipider til fremstilling af et lægemiddel til forebyggelse af adhæsioner
CA2417935A1 (en) Anti-inflammatory medicament
UA90249C2 (uk) Комбінація, що містить кандесартан та розувастатин, фармацевтична композиція, яка її містить, та застосування
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
SE0001916D0 (sv) Novel formulation
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
AR011707A1 (es) Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento.